Neogen (NASDAQ:NEOG) 株価情報

NEOGEN CORP

Neogen

Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety. In food safety, Neogen performs diagnostics to detect unintended substances in food and animal feed, such as pathogens, allergens, and drug residues, for food and feed processing companies. In animal safety, Neogen sells veterinary instruments, pharmaceuticals, disinfectants, and genomics tests for animals, including cattle, horses, and canines. Sales in the United States account for maximum revenue, and it also has its presence in United Kingdom and other countries.

News

Movers

ACLS

AGIO

HALO

IRTC

LBTYB

LEGN

NEOG

NUVL

NVAX

NVDA

SMAR

TWST

VRNT

これらの中型株は直近1週間で最も好調のパフォーマンスを示しました。あなたのポートフォリオには入っていますか？

直近1週間高パフォーマンスを示したのは、中型株

Neogen Corp

NEOGAMES SA SHS USD

NeoGenomics Inc

Piper Sandler analyst David Westenberg maintains Neogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOG#NASDAQ">NEOG</a>) with a Neutral and lowers the price target from $6.4 to $5.

Price Target

Analyst Ratings

Piper Sandler Maintains Neutral on Neogen, Lowers Price Target to $5

Food safety solutions provider Neogen Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOG#NASDAQ">NEOG</a>) shares are <a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener">trading higher on Monday</a> after selling its Cleaners &amp; Disinfectants Business.
The company has finalized an agreement to divest its worldwide cleaners and disinfectants division to Kersia Group, a leading company in hygiene and biosecurity solutions, in a cash transaction valued at $130 million.
The agreement includes additional contingent payments based on the business's future performance. The transaction, subject to regulatory approval, is expected to conclude in the first quarter of FY26.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/25/04/44895043/target-rolls-out-standalone-flower-brand-good-little-garden" rel="noreferrer noopener">Target Rolls Out Standalone Flower Brand ‘Good Little Garden'</a>
"The sale of our cleaners and disinfectants business further focuses Neogen on food safety diagnostics and continuing to build on our leadership position in what we believe is an attractive end market with long-term tailwinds," said President and CEO of Neogen, John Adent.
"We expect Kersia's prioritization of investment and growth in the biosecurity market will benefit the business and provide sharpened strategic focus to maximize its potential for continued growth."
Proceeds from the sale will enable Neogen to eliminate its $100 million revolving credit debt, following a recent refinancing move.
The company expects the transaction to improve profit margins and lower its net leverage ratio by roughly 0.4x on a pro forma basis.
Neogen's disinfectant and cleaning product line, which brings in about $60 million in yearly revenue, supports various livestock markets such as poultry, swine, and ruminants.
Price Action: NEOG shares traded higher by 7.14% at $4.71 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/25/04/44897010/chipotle-to-open-first-mexico-restaurant-by-2026" target="_blank" rel="noreferrer noopener">Chipotle To Open First Mexico Restaurant By 2026</a></li>
</ul>

Asset Sales

General

Testing Firm Neogen Offloads Cleaners Division To Kersia In $130 Million Deal

Food safety company Neogen Corp&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOG#NASDAQ">NEOG</a>) on Monday agreed to sell its global cleaners and disinfectants business to Kersia Group.
Kersia offers biosecurity, disinfection <a href="https://www.benzinga.com/pressreleases/25/04/b44896153/neogen-announces-sale-of-cleaners-disinfectants-business" target="_blank" rel="noreferrer noopener">and hygiene solutions</a>.
Deal consideration consists of $130 million in cash at closing plus contingent consideration tied to the future performance of the business.
Neogen says the transaction is expected to be accretive to margins and close in the first quarter of the company&#8217;s 2026 fiscal year.
The net proceeds will be used to fully repay the $100 million drawn on the company&#8217;s revolving credit facility in the recent term loan refinancing, with the divestiture expected to reduce the company&#8217;s net leverage ratio by approximately 0.4x on a pro forma basis.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/04/44709995/neogen-q3-earnings-fall-short-on-expectations-cuts-guidance-amid-macro-headwinds-and-tariff-concerns" rel="noreferrer noopener">Neogen Q3 Earnings Fall Short On Expectations, Cuts Guidance Amid Macro Headwinds And Tariff Concerns</a>
&#8220;The sale of our cleaners and disinfectants business further focuses Neogen on food safety diagnostics and continuing to build on our leadership position in what we believe is an attractive end market with long-term tailwinds,&#8221; said John Adent, president and CEO of Neogen. 
&#8220;The cleaners and disinfectants business has been a strong contributor to our Animal Safety segment and Neogen is committed to a smooth transition for customers, employees and other stakeholders. We expect Kersia&#8217;s prioritization of investment and growth in the biosecurity market will benefit the business and provide sharpened strategic focus to maximize its potential for continued growth.&#8221;
With approximately $60 million in annual revenue, Neogen&#8217;s cleaners and disinfectants are used in a range of livestock applications, including swine, poultry, and ruminant operations.
Earlier this month, Neogen refinanced the remaining $550 million principal of its original $650 million term loan, as well as its revolving credit facility, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44665667/neogen-announces-refinancing-of-term-loan-and-revolving-credit-facility" rel="noreferrer noopener">due in August 2027</a>.
The new $450 million term loan and $250 million revolving credit facility mature in April 2030, extending the previous maturity by over two and a half years.
With an upsizing of the company&#8217;s revolving credit facility from $150 million to $250 million and an initial draw of $100 million, the refinancing represents a leverage-neutral transaction.
&#8220;We are pleased to complete this refinancing, which not only maintains our current liquidity position and extends the maturity of the term loan and revolving credit facility, but also results in a lower interest rate,&#8221; said David Naemura, CFO and COO of Neogen.
NEOG Price Action: Neogen stock is up 4.90% at $4.61 at publication on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/04/44894989/astrazeneca-daiichi-sankyos-multi-billion-dollar-cancer-drug-shows-superior-efficacy-across-broad-her2-positive-metastatic-breast-cancer-patients" target="_blank" rel="noreferrer noopener">AstraZeneca- Daiichi Sankyo&#8217;s Multi-Billion Dollar Cancer Drug Shows Superior Efficacy Across Broad HER2 Positive Metastatic Breast Cancer Patients</a></li>
</ul>
Photo: Shutterstock

Health Care

Neogen Seeks To Cut Debt, Streamline Focus With Sale Of Cleaners, Disinfectants Business For $130 Million

Neogen Enters Agreement To Sell Its Cleaners & Disinfectants Business To Kersia Group For $130M In Cash; Says Transaction Is Expected To Be Accretive To Margins And Close In Q1 Of 2026 Fiscal Year

Piper Sandler analyst David Westenberg maintains Neogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOG#NASDAQ">NEOG</a>) with a Neutral and lowers the price target from $13 to $6.5.

Piper Sandler Maintains Neutral on Neogen, Lowers Price Target to $6.5

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Wells Fargo raised Toast, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOST#NYSE">TOST</a>) price target from $30 to $39. Wells Fargo analyst Jeff Cantwell upgraded the rating from Underweight to Overweight. Toast shares closed at $34.38 on Wednesday. <a href="https://www.benzinga.com/quote/TOST/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Guggenheim slashed the price target for Neogen Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOG#NASDAQ">NEOG</a>) from $15 to $13. Guggenheim analyst Subbu Nambi maintained a Buy rating. Neogen shares closed at $5.02 on Wednesday. <a href="https://www.benzinga.com/quote/NEOG/analyst-ratings">See how other analysts view this stock.</a></li>
<li>UBS lowered BorgWarner Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWA#NYSE">BWA</a>) price target from $38 to $31. UBS analyst Joseph Spak downgraded the stock from Buy to Neutral. BorgWarner shares closed at $26.89 on Wednesday. See how other analysts <a href="https://www.benzinga.com/quote/BWA/analyst-ratings">view this stock</a>.</li>
<li>Truist Securities cut the price target for IQVIA Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IQV#NYSE">IQV</a>) from $263 to $216. Truist Securities analyst Jailendra Singh maintained a Buy rating. IQVIA shares closed at $157.02 on Wednesday. <a href="https://www.benzinga.com/quote/IQV/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities cut the price target for Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) from $171 to $159. B of A Securities analyst Tim Anderson maintained a Neutral rating. Johnson &amp; Johnson shares closed at $150.97 on Wednesday. <a href="https://www.benzinga.com/quote/JNJ/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Loop Capital slashed Manhattan Associates, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MANH#NASDAQ">MANH</a>) price target from $275 to $170. Loop Capital analyst Mark Schappel downgraded the stock from Buy to Hold. Manhattan Associates shares settled at $166.26 on Wednesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view </a><a href="https://www.benzinga.com/quote/MANH/analyst-ratings">this </a><a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">stock</a>.</li>
<li>Barclays cut ManpowerGroup Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAN#NYSE">MAN</a>) price target from $55 to $50. Barclays analyst Manav Patnaik upgraded the stock from Underweight to Equal-Weight. ManpowerGroup shares closed at $52.87 on Wednesday. <a href="https://www.benzinga.com/quote/MAN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Truist Securities slashed Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) price target from $265 to $230. Truist Securities analyst Youssef Squali maintained a Buy rating. Amazon shares closed at $191.10 on Wednesday.  <a href="https://www.benzinga.com/quote/AMZN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Mizuho cut the price target for NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) from $4.2 to $3.5. Mizuho analyst Vijay Rakesh maintained a Neutral rating. NIO shares settled at $3.31 on Wednesday. <a href="https://www.benzinga.com/quote/NIO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler slashed Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) price target from $208 to $185. Piper Sandler analyst Thomas Champion maintained an Overweight rating. Alphabet shares closed at $158.71 on Wednesday. <a href="https://www.benzinga.com/quote/googl/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying GOOGL stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="577" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10092133/image-69-1024x577.png" alt="" class="wp-image-865996" style="width:518px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10092133/image-69-1024x577.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10092133/image-69-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10092133/image-69-768x433.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10092133/image-69.png 1103w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:
<ul>
<li> <a href="https://www.benzinga.com/25/04/44710375/top-2-materials-stocks-that-may-fall-off-a-cliff-this-quarter">Top 2 Materials Stocks That May Fall Off A Cliff This Quarter</a> </li>
</ul>
Photo via Shutterstock

Markets

Trading Ideas

AMZN

GOOGL

MANH

TOST

Alphabet To $185? Here Are 10 Top Analyst Forecasts For Thursday

Guggenheim analyst Subbu Nambi maintains Neogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOG#NASDAQ">NEOG</a>) with a Buy and lowers the price target from $15 to $13.

Guggenheim Maintains Buy on Neogen, Lowers Price Target to $13

<h3>Gainers</h3>
<ul>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) stock moved upwards by 179.4% to $8.16 during Wednesday's regular session. The company's market cap stands at $5.3 million. </li>
<li>Phio Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHIO#NASDAQ">PHIO</a>) shares moved upwards by 67.33% to $1.69. The market value of their outstanding shares is at $8.0 million. </li>
<li>SCWorx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WORX#NASDAQ">WORX</a>) shares rose 42.58% to $1.14. The company's market cap stands at $2.3 million. </li>
<li>Hepion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEPA#NASDAQ">HEPA</a>) stock moved upwards by 26.68% to $0.52. </li>
<li>Lexeo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXEO#NASDAQ">LXEO</a>) stock moved upwards by 19.73% to $2.18. The company's market cap stands at $72.3 million. </li>
<li>VolitionRX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VNRX#AMEX">VNRX</a>) stock rose 19.49% to $0.55. The market value of their outstanding shares is at $54.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Vincerx Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINC#NASDAQ">VINC</a>) stock fell 55.2% to $0.24 during Wednesday's regular session. </li>
<li>Neogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOG#NASDAQ">NEOG</a>) stock fell 38.85% to $4.3. The market value of their outstanding shares is at $933.9 million. The company's, Q3 earnings came out today. </li>
<li>Salarius Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>) stock fell 37.21% to $0.51. </li>
<li>Aardvark Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AARD#NASDAQ">AARD</a>) stock fell 31.01% to $5.03. The market value of their outstanding shares is at $107.5 million. </li>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) stock decreased by 29.37% to $0.01. </li>
<li>ZyVersa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVSA#NASDAQ">ZVSA</a>) shares declined by 22.05% to $0.99. The company's market cap stands at $2.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AARD

HEPA

LGMK

LXEO

PHIO

SLRX

VERO

VINC

VNRX

WORX

ZVSA

12 Health Care Stocks Moving In Wednesday's Intraday Session

U.S. stocks traded mixed midway through trading, with the Dow Jones index falling more than 100 points on Wednesday.
The Dow traded down 0.29% to 37,535.75 while the NASDAQ climbed 0.56% to 15,353.21. The S&amp;P 500 also fell, dropping, 0.15% to 4,975.48.
Check This Out: <a href="https://www.benzinga.com/25/04/44709125/this-apple-analyst-is-no-longer-bearish-here-are-top-5-upgrades-for-wednesday">This Apple Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday</a>
Leading and Lagging Sectors Information technology shares surged by 1.8% on Wednesday.
In trading on Wednesday, energy shares fell by 2%.
Top Headline
The Simply Good Foods Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMPL#NASDAQ">SMPL</a>) posted better-than-expected quarterly results.
The company, led by CEO Geoff Tanner, reported second-quarter FY25 sales growth of 15% year-on-year to $359.65 million. It beat the analyst consensus estimate of $354.4 million. Adjusted EPS of 46 cents beat the consensus estimate of 40 cents.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Venus Concept Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) shares shot up 242% to $9.84 after the company announced it secured $23.24 million in bridge financing from Madryn Health Partners.</li>
<li>Shares of Phio Pharmaceuticals Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHIO#NASDAQ">PHIO</a>)got a boost, surging 116% to $2.18 after the company announced its Safety Monitoring Committee recommended dose escalation in the Phase 1b trial of PH-762.</li>
<li>22nd Century Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) shares were also up, gaining 19% to $1.25 after the company announced new agreements from former customers to supply filtered cigar products.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Neogen Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOG#NASDAQ">NEOG</a>) shares dropped 29% to $4.98 after the company reported worse-than-expected third-quarter financial results and issued FY25 sales guidance below estimates.</li>
<li>Shares of Vincerx Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINC#NASDAQ">VINC</a>) were down 54% to $0.2323 after the company announced it terminated its letter of intent with Global Digital regarding a potential merger.</li>
<li>Bloom Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) was down, falling 10% to $15.32. Redburn Atlantic analyst Skye Landon downgraded Bloom Energy from Neutral to Sell and lowered the price target from $14.5 to $10.</li>
</ul>
Commodities In commodity news, oil traded down 4% to $57.24 while gold traded up 3.4% at $3,091.90.
Silver traded up 2.4% to $30.42 on Wednesday, while copper rose 2% to $4.2280.
Euro zone
European shares were lower today. The eurozone's STOXX 600 dipped 2.92%, Germany's DAX 40 dipped 2.39% and France's CAC 40 tumbled 2.74%. Spain's IBEX 35 Index fell 1.71%, while London's FTSE 100 fell 2.52%.
Asia Pacific Markets
Asian markets closed mixed on Wednesday, with Japan's Nikkei 225 falling 3.93%, China's Shanghai Composite gaining 1.31%, Hong Kong's Gang Seng index rising 0.68% and India's BSE Sensex falling 0.51%.
Economics
U.S. mortgage application volumes climbed by 20% from the previous week during the first week of April. 
U.S. crude oil inventories climbed by 2.553 million barrels in the week ended April 4, compared to market estimates of a 2.2 million gain.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/04/44707561/top-3-financial-stocks-that-could-blast-off-in-april">Top 3 Financial Stocks That Could Blast Off In April</a> </li>
</ul>
Photo via Shutterstock

Earnings

Equities

Eurozone

Commodities

Intraday Update

SMPL

XXII

Crude Oil Down 4%; Neogen Shares Plunge After Q3 Results

WIIM

Neogen Corporation shares are trading lower after the company reported worse-than-expected Q3 financial results and issued FY25 sales guidance below estimates.

Neogen Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOG#NASDAQ">NEOG</a>) reported third-quarter 2025 adjusted EPS of 10 cents on Wednesday, down from 12 cents a year ago, missing the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus of 11 cents</a>.
The company reported sales of $220.98 million, down 3.4% year over year, missing the consensus of $224.88 million.
Core revenue, which excludes the impacts of foreign currency translation and acquisitions completed and product lines discontinued in the last 12 months, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44707568/neogen-announces-third-quarter-2025-results" rel="noreferrer noopener">increased by 0.2%</a>.
Acquisitions and discontinued product lines had a negative impact of 0.5% while foreign currency had a negative impact of 3.1%.
The gross margin was 49.9% down from 51.1% a year ago, mainly due to lower revenue and higher integration costs. Excluding integration and restructuring costs, gross margin was 51.5% in the third quarter compared to 51.8% in the prior-year quarter.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44698463/cartesian-therapeutics-reports-strong-12-month-data-for-lead-cell-therapy-in-myasthenia-gravis-patients" rel="noreferrer noopener">Cartesian Therapeutics Reports Strong 12-Month Data For Lead Cell Therapy In Myasthenia Gravis Patients</a>
Third-quarter Adjusted EBITDA was $48.5 million, representing an adjusted EBITDA margin of 22%, compared with $52.7 million and a margin of 23% a year earlier.
Revenues for the Food Safety segment were $152.7 million, a decrease of 3.2%, consisting of 1.5% core growth, a negative 0.3% impact from discontinued product lines, and a negative foreign currency impact of 4.4%.
<ul>
<li>Core growth was driven largely by biosecurity and bacterial and general sanitation product categories, which benefited from strong growth in pathogen detection products.</li>
</ul>
Revenues for the Animal Safety segment were $68.2 million, a decrease of 4%, consisting of a 2.6% core revenue decline, an unfavorable 0.4% foreign currency impact and a negative 1% impact from discontinued product lines.
<ul>
<li>Growth was led by the animal care and other and biosecurity product categories, particularly in small-animal supplements, rodent control, and cleaner and disinfectant products, and offset by a decline in the vet instruments product category.</li>
</ul>
The company&#8217;s Genomics business experienced a core revenue decline in the mid-single-digit range. Increased sales into bovine markets were offset by declines in other areas, consistent with the focused restructuring activities executed in the second quarter.
Guidance: The company is updating its full-year outlook, primarily due to lower-than-expected third-quarter results, the rising level of macroeconomic uncertainty affecting the company&#8217;s end markets, and the expected impact of tariffs in the fourth quarter.
Neogen expects fiscal year 2025 sales of approximately $895 million, down from prior guidance of $905 million-$925 million and consensus of $910.23 million.
The company forecasts 2025 adjusted EBITDA of approximately $195 million compared to prior guidance of $205 million-$215 million.
Management Update: Neogen CEO John Adent will be stepping down after eight years the company. Adent will continue to serve in his existing roles until his successor <a href="https://www.benzinga.com/pressreleases/25/04/b44707614/neogen-announces-ceo-transition" target="_blank" rel="noreferrer noopener">has been appointed</a>.
Price Action: NEOG stock is down 17.6% at $5.80 during the premarket session at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44698379/argenxs-flagship-drug-vyvgart-shows-sustained-disease-control-in-rare-neuromuscular-disease-patients" target="_blank" rel="noreferrer noopener">Argenx&#8217;s Flagship Drug Vyvgart Shows Sustained Disease Control In Rare Neuromuscular Disease Patients</a></li>
</ul>
Photo: Shutterstock/MacroEcon

Guidance

Management

Neogen Q3 Earnings Fall Short On Expectations, Cuts Guidance Amid Macro Headwinds And Tariff Concerns

Neogen CEO John Adent To Step Down, Will Continue To Serve Until Successor Is Appointed

<ul>
<li>Neogen is updating its full-year outlook, primarily due to third-quarter results being lower than expected and the effect of the rising level of macroeconomic uncertainty on the Company's end markets, as well as the expected impact of tariffs in the fourth quarter.</li>
<li>The Company now expects capital expenditures to be approximately $100 million, reflecting the lower Adjusted EBITDA and pull-forward of some level of integration capex into fiscal 2025.&nbsp;</li>
</ul>

Neogen Expects FY2025 Sales Of Approximately $895M Vs. Prior Guidance Of $905M-$925M And Consensus Of $910.23M And Adjusted EBITDA Of Approximately $195M Vs. Prior Guidance Of $205M-$215M

Neogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOG#NASDAQ">NEOG</a>) reported quarterly earnings of $0.10 per share which missed the analyst consensus estimate of $0.11 by 9.09 percent. This is a 16.67 percent decrease over earnings of $0.12 per share from the same period last year. The company reported quarterly sales of $220.98 million which missed the analyst consensus estimate of $224.88 million by 1.74 percent. This is a 3.42 percent decrease over sales of $228.81 million the same period last year.

Neogen Q3 2025 Adj EPS $0.10 Misses $0.11 Estimate, Sales $220.98M Miss $224.88M Estimate

<h3>Companies Reporting Before The Bell</h3>
• Neogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOG#NASDAQ">NEOG</a>) is projected to report quarterly earnings at $0.12 per share on revenue of $224.23 million. 
• Target Hospitality (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TH#NASDAQ">TH</a>) is likely to report quarterly loss at $0.03 per share on revenue of $29.18 million. 
• Theratechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THTX#NASDAQ">THTX</a>) is projected to report quarterly loss at $0.02 per share on revenue of $29.18 million. 
• Delta Air Lines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>) is expected to report quarterly earnings at $0.80 per share on revenue of $13.39 billion. 
• Simply Good Foods (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMPL#NASDAQ">SMPL</a>) is estimated to report earnings for its second quarter. 
<h3>Companies Reporting After The Bell</h3>
• Richardson Electronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RELL#NASDAQ">RELL</a>) is estimated to report quarterly earnings at $0.10 per share on revenue of $56.90 million. 
• Pure Cycle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCYO#NASDAQ">PCYO</a>) is projected to report earnings for its second quarter. 
• Lakeland Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAKE#NASDAQ">LAKE</a>) is likely to report quarterly earnings at $0.44 per share on revenue of $47.10 million. 
• BBB Foods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TBBB#NYSE">TBBB</a>) is likely to report quarterly earnings at $0.04 per share on revenue of $789.13 million. 
• Calamos Glb Total (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGO#NASDAQ">CGO</a>) is likely to report earnings for its second quarter. 
• Constellation Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>) is projected to report quarterly earnings at $2.49 per share on revenue of $2.24 billion. 
• Pricesmart (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSMT#NASDAQ">PSMT</a>) is estimated to report quarterly earnings at $1.41 per share on revenue of $1.34 billion. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

LAKE

PCYO

PSMT

RELL

TBBB

THTX

Earnings Scheduled For April 9, 2025

Neogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOG#NASDAQ">NEOG</a>) is set to give its latest quarterly earnings report on Wednesday, 2025-04-09. Here's what investors need to know before the announcement.
Analysts estimate that Neogen will report an earnings per share (EPS) of $0.12. 
Anticipation surrounds Neogen's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Earnings History Snapshot</h3>
Last quarter the company beat EPS by $0.01, which was followed by a 0.0% drop in the share price the next day.
Here's a look at Neogen's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.10</td>
<td>0.08</td>
<td>0.11</td>
<td>0.14</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.11</td>
<td>0.07</td>
<td>0.10</td>
<td>0.12</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-5.0%</td>
<td>5.0%</td>
<td>-3.0%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1744120853_0.png" alt="eps graph" />
<h3>Performance of Neogen Shares</h3>
Shares of Neogen were trading at $7.85 as of April 07. Over the last 52-week period, shares are down 37.2%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/NEOG/earnings">To track all earnings releases for Neogen visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Neogen's Earnings: A Preview

U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Monday.
Shares of Incyte Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) fell sharply in today's pre-market trading after reporting topline results from two Phase 3 clinical trials of Povorcitinib in patients with Hidradenitis Suppurativa.
Incyte shares dipped 15.3% to $57.50 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>USA Rare Earth, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USAR#NASDAQ">USAR</a>) fell 13.8% to $16.00 in pre-market trading after jumping over 70% on Friday.</li>
<li>Affirm Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) dipped 12.1% to $44.01 in pre-market trading after gaining around 7% on Friday.</li>
<li>Tyra Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TYRA#NASDAQ">TYRA</a>) fell 8.7% to $10.50 in pre-market trading after gaining 7% on Friday.</li>
<li>Omeros Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) shares dipped 4.4% to $8.05 in pre-market trading after gaining 7% on Friday.</li>
<li>Neogen Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOG#NASDAQ">NEOG</a>) fell 3.8% to $8.71 in pre-market trading.</li>
<li>Innventure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INV#NASDAQ">INV</a>) slipped 3.3% to $7.62 in pre-market trading.</li>
<li>Kamada Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KMDA#NASDAQ">KMDA</a>) fell 3% to $6.77 in pre-market trading.</li>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) slipped 1% to $ 247.77 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/04/38311966/izea-worldwide-and-2-other-stocks-under-3-insiders-are-buying">IZEA Worldwide And 2 Other Stocks Under $3 Insiders Are Buying</a></li>
</ul>
Photo: Shutterstock

Pre-Market Outlook

AFRM

INCY

KMDA

OMER

TSLA

TYRA

USAR

Incyte, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session

The claim was withdrawn following a mutual agreement, with no admission of wrongdoing by Neogen.
In the coming weeks,&nbsp;Lansing warehouse shipping clerks and material handling employees will have the opportunity to vote in an election to determine whether they wish to unionize.

Neogen Says National Labor Relations Board Has Withdrawn Its Unfair Labor Practices Claim Against Company

Piper Sandler analyst David Westenberg reiterates Neogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOG#NASDAQ">NEOG</a>) with a Neutral and lowers the price target from $16.5 to $13.

Reiteration

Piper Sandler Reiterates Neutral on Neogen, Lowers Price Target to $13

Neogen Corporation Launched It's Igenity BCHF To Improve Overall Bovine Heart Health Standards

Press Releases

Neogen Announces Preliminary¹ Second-Quarter 2025 Results

Neogen® Launches New MDA2 Quantitative Salmonella Molecular Detection Assay

Neogen® Introduces Igenity® BCHF to Help Industry Mitigate Bovine Congestive Heart Failure Risk

NLRB Withdraws Unfair Labor Practices Claim Against Neogen®

Mutual Funds

DoorDash, TKO Group Holdings, Williams-Sonoma and Expand Energy Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600

Comments

Neogen

ニュース

パートナーシップ

ベンジンガ・グローバル